Pharmaceuticals, Biotechnology and Life Sciences
Lonza has launched two new rapid monocyte activation test (MAT) systems, the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, to streamline and simplify rabbit-free pyrogen testing.
Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS)
Global capsule and equipment developer and manufacturer, Lonza has introduced an enhanced product line aimed at tackling concerns around bias during blinded clinical trials.
Lonza and the Swedish company Cellink have partnered to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to optimize and increase access to complete 3D cell culture workflows.
On 16 June, Lonza will host a free 60-minute webinar on the latest regulatory developments surrounding the use of the recombinant Factor C (rFC) assay for endotoxin detection in parenteral pharmaceuticals and implantable medical devices.
Lonza Sales AG, through its Bioscience Division, announced Thursday a strategic partnership with Sanquin Reagents B.V. for the commercialization of a range of specialized reagents for pyrogen testing of parenteral pharmaceuticals and medical devices using the Monocyte Activation Test (MAT).
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
Swiss-based Lonza has launched the TheraPEAK SfAAV Medium, the first chemically defined, non-animal origin medium designed specifically for the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications.
Sanofi and Lonza will invest €270 million (CHF 290 million) in a mammalian cell culture site for monoclonal antibody production in Swiss town of Visp, planned for opening in 2020.